Correlation Between Virax Biolabs and Liquidia Technologies

Can any of the company-specific risk be diversified away by investing in both Virax Biolabs and Liquidia Technologies at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Virax Biolabs and Liquidia Technologies into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Virax Biolabs Group and Liquidia Technologies, you can compare the effects of market volatilities on Virax Biolabs and Liquidia Technologies and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Virax Biolabs with a short position of Liquidia Technologies. Check out your portfolio center. Please also check ongoing floating volatility patterns of Virax Biolabs and Liquidia Technologies.

Diversification Opportunities for Virax Biolabs and Liquidia Technologies

-0.66

Correlation Coefficient

Virax Biolabs  Liquidia Technologies

Excellent diversification

The 3 months correlation between Virax and Liquidia is -0.66. Overlapping area represents the amount of risk that can be diversified away by holding Virax Biolabs Group and Liquidia Technologies in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Liquidia Technologies and Virax Biolabs is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Virax Biolabs Group are associated (or correlated) with Liquidia Technologies. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Liquidia Technologies has no effect on the direction of Virax Biolabs i.e., Virax Biolabs and Liquidia Technologies go up and down completely randomly.

Pair Corralation between Virax Biolabs and Liquidia Technologies

Given the investment horizon of 90 days Virax Biolabs Group is expected to generate 3.36 times more return on investment than Liquidia Technologies. However, Virax Biolabs is 3.36 times more volatile than Liquidia Technologies. It trades about 0.06 of its potential returns per unit of risk. Liquidia Technologies is currently generating about 0.07 per unit of risk. If you would invest  171.00  in Virax Biolabs Group on September 3, 2024 and sell it today you would earn a total of  26.00  from holding Virax Biolabs Group or generate 15.2% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Virax Biolabs Group  vs.  Liquidia Technologies

Virax Biolabs Group

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Virax Biolabs Group has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Liquidia Technologies

Risk-Adjusted Performance

10 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Liquidia Technologies are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unfluctuating fundamental indicators, Liquidia Technologies sustained solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Virax Biolabs and Liquidia Technologies

The main advantage of trading using opposite Virax Biolabs and Liquidia Technologies positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Virax Biolabs position performs unexpectedly, Liquidia Technologies can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Liquidia Technologies will offset losses from the drop in Liquidia Technologies' long position.

The idea behind Virax Biolabs Group and Liquidia Technologies pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.